These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38897452)

  • 1. RB1 Genetic Alterations in Estrogen Receptor-Positive Breast Carcinomas: Correlation With Neuroendocrine Differentiation.
    Schwartz CJ; Marra A; Selenica P; Gazzo A; Tan K; Ross D; Razavi P; Chandarlapaty S; Weigelt B; Reis-Filho JS; Brogi E; Pareja F; Wen HY
    Mod Pathol; 2024 Aug; 37(8):100541. PubMed ID: 38897452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma.
    Shamir ER; Devine WP; Pekmezci M; Umetsu SE; Krings G; Federman S; Cho SJ; Saunders TA; Jen KY; Bergsland E; Jones K; Kim GE; Kakar S; Chiu CY; Joseph NM
    Mod Pathol; 2019 Feb; 32(2):290-305. PubMed ID: 30237525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonlobular Invasive Breast Carcinomas with Biallelic Pathogenic CDH1 Somatic Alterations: A Histologic, Immunophenotypic, and Genomic Characterization.
    Derakhshan F; Da Cruz Paula A; Selenica P; da Silva EM; Grabenstetter A; Jalali S; Gazzo AM; Dopeso H; Marra A; Brown DN; Ross DS; Mandelker D; Razavi P; Chandarlapaty S; Wen HY; Brogi E; Zhang H; Weigelt B; Pareja F; Reis-Filho JS
    Mod Pathol; 2024 Feb; 37(2):100375. PubMed ID: 37925055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation sequencing of salivary high-grade neuroendocrine carcinomas identifies alterations in RB1 and the mTOR pathway.
    Goyal B; Duncavage EJ; Martinez D; Lewis JS; Chernock RD
    Exp Mol Pathol; 2014 Dec; 97(3):572-8. PubMed ID: 25446844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
    Simbolo M; Mafficini A; Sikora KO; Fassan M; Barbi S; Corbo V; Mastracci L; Rusev B; Grillo F; Vicentini C; Ferrara R; Pilotto S; Davini F; Pelosi G; Lawlor RT; Chilosi M; Tortora G; Bria E; Fontanini G; Volante M; Scarpa A
    J Pathol; 2017 Mar; 241(4):488-500. PubMed ID: 27873319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
    Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
    J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next generation sequencing of Cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation.
    Harms PW; Collie AM; Hovelson DH; Cani AK; Verhaegen ME; Patel RM; Fullen DR; Omata K; Dlugosz AA; Tomlins SA; Billings SD
    Mod Pathol; 2016 Mar; 29(3):240-8. PubMed ID: 26743471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The genetic landscape of breast carcinomas with neuroendocrine differentiation.
    Marchiò C; Geyer FC; Ng CK; Piscuoglio S; De Filippo MR; Cupo M; Schultheis AM; Lim RS; Burke KA; Guerini-Rocco E; Papotti M; Norton L; Sapino A; Weigelt B; Reis-Filho JS
    J Pathol; 2017 Feb; 241(3):405-419. PubMed ID: 27925203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-Generation Sequencing of Retinoblastoma Identifies Pathogenic Alterations beyond RB1 Inactivation That Correlate with Aggressive Histopathologic Features.
    Afshar AR; Pekmezci M; Bloomer MM; Cadenas NJ; Stevers M; Banerjee A; Roy R; Olshen AB; Van Ziffle J; Onodera C; Devine WP; Grenert JP; Bastian BC; Solomon DA; Damato BE
    Ophthalmology; 2020 Jun; 127(6):804-813. PubMed ID: 32139107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining triple-negative breast cancer with neuroendocrine differentiation (TNBC-NED).
    Hacking SM; Yakirevich E; Wang Y
    J Pathol Clin Res; 2023 Jul; 9(4):313-321. PubMed ID: 37082801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retinoblastoma co-repressor 1 (RB) and cyclin-dependent kinase inhibitor (CDKN) as a multi-gene panel for differentiating pulmonary from non-pulmonary origin in metastatic neuroendocrine carcinomas.
    Krishnamurthy K; Cusnir M; Schwartz M; Sriganeshan V; Poppiti RJ
    Pathol Res Pract; 2020 Sep; 216(9):153051. PubMed ID: 32825935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder.
    Liu F; Li Y; Ying D; Qiu S; He Y; Li M; Liu Y; Zhang Y; Zhu Q; Hu Y; Liu L; Li G; Pan W; Jin W; Mu J; Cao Y; Liu Y
    Signal Transduct Target Ther; 2021 Feb; 6(1):55. PubMed ID: 33563892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
    Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
    Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Grading of Neuroendocrine Carcinomas: Correlation of
    Liverani C; Bongiovanni A; Mercatali L; Foca F; Pieri F; De Vita A; Spadazzi C; Miserocchi G; Recine F; Riva N; Nicolini S; Severi S; Martinelli G; Ibrahim T
    Dis Markers; 2018; 2018():6878409. PubMed ID: 30627226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic alterations and their association with clinicopathologic characteristics in advanced breast carcinomas: focusing on clinically actionable genetic alterations.
    Freitag CE; Mei P; Wei L; Parwani AV; Li Z
    Hum Pathol; 2020 Aug; 102():94-103. PubMed ID: 32445652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.
    Cimino-Mathews A; Ye X; Meeker A; Argani P; Emens LA
    Hum Pathol; 2013 Oct; 44(10):2055-63. PubMed ID: 23701942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. REST Inactivation and Coexpression of ASCL1 and POU3F4 Are Necessary for the Complete Transformation of RB1/TP53-Inactivated Lung Adenocarcinoma into Neuroendocrine Carcinoma.
    Masawa M; Sato-Yazawa H; Kashiwagi K; Ishii J; Miyata-Hiramatsu C; Iwamoto M; Kohno K; Miyazawa T; Onozaki M; Noda S; Shimizu Y; Niho S; Yazawa T
    Am J Pathol; 2022 Jun; 192(6):847-861. PubMed ID: 35367201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma.
    Ohmoto A; Sato Y; Asaka R; Fukuda N; Wang X; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Toshiyasu T; Mitani H; Takeuchi K; Mori S; Takahashi S
    Mod Pathol; 2021 Nov; 34(11):1979-1989. PubMed ID: 34247193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases.
    Schrijver WAME; Selenica P; Lee JY; Ng CKY; Burke KA; Piscuoglio S; Berman SH; Reis-Filho JS; Weigelt B; van Diest PJ; Moelans CB
    Cancer Res; 2018 Jun; 78(12):3112-3121. PubMed ID: 29615433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.